Luspatercept is a novel fusion protein that blocks TGF-β superfamily ligands, such as GDF-11 and activin B, thereby restoring late-stage erythropoiesis in anemic lower-risk MDS patients [8, 9]. The gene discussed is GDF11; the disease is myelodysplastic syndrome.